Reviewing Magenta Therapeutics Inc. (MGTA)’s and PTC Therapeutics Inc. (NASDAQ:PTCT)’s results – FinanceMercury

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Magenta Therapeutics Inc. (NASDAQ:MGTA) and PTC Therapeutics Inc. (NASDAQ:PTCT). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Table 1 demonstrates Magenta Therapeutics Inc. and PTC Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Liquidity

The Current Ratio and Quick Ratio of Magenta Therapeutics Inc. are 17.1 and 17.1 respectively. Its competitor PTC Therapeutics Inc.s Current Ratio is 3.3 and its Quick Ratio is 3.2. Magenta Therapeutics Inc. can pay off short and long-term obligations better than PTC Therapeutics Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Magenta Therapeutics Inc. and PTC Therapeutics Inc.

Meanwhile, PTC Therapeutics Inc.s consensus target price is $50.67, while its potential upside is 25.11%.

Insider & Institutional Ownership

Institutional investors owned 85.4% of Magenta Therapeutics Inc. shares and 85.61% of PTC Therapeutics Inc. shares. Insiders owned roughly 2.2% of Magenta Therapeutics Inc.s shares. Comparatively, PTC Therapeutics Inc. has 0.3% of its share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Magenta Therapeutics Inc.s stock price has bigger growth than PTC Therapeutics Inc.

Summary

PTC Therapeutics Inc. beats on 8 of the 11 factors Magenta Therapeutics Inc.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury